Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27865548 | 0.97 | PTGS1 (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL8620435 | 0.83 | APP (0.46) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL6736117 | 0.81 | APP (0.44) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL11872935 | 0.80 | ALDH1A1 (0.47) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL8812367 | 0.79 | APP (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL7204473 | 0.79 | APP (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL162508 | 0.78 | LMNA (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL776557 | 0.78 | PTGS1 (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL19764245 | 0.78 | PTGS1 (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL17452116 | 0.78 | PTGS1 (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718617-B1 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | claimed |
| EP-1718617-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | claimed |
| WO-2005080343-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | claimed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| CN-115052875-A | 4- (4- (4, 5-dihydroisoxazol-3-yl) thiazol-2-yl) piperidinethimine or sulfoximine derivatives as fungicides for crop protection and related compounds | PI工业有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114746499-A | Flame retardant polymer composition | 科德宝两合公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114341131-A | Novel oxadiazole compounds comprising a 5-membered heteroaromatic ring for controlling or preventing phytopathogenic fungi | PI工业有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-4605745-A | PHASE TRANSFER CATALYSTS; AROMATIC ETHERS IN IMPROVED YIELDS | GENERAL ELECTRIC COMPANY (US) | 1986-08-12 | — | — | US | disclosed |
| US-4513141-A | BY DISPLACING REACTIVE RADICALS ON AROMATIC NUCLEUS | GENERAL ELECTRIC COMPANY (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0126950-A2 | Method for making aromatic ethers and catalyst used in such method | GENERAL ELECTRIC COMPANY (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4281116-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4260745-A | 3-Halo cephalosporins | ELI LILLY AND COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| US-4252950-A | ANTIBIOTICS, BACTERICIDES, FUNGICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| US-4208515-A | 3-Halo cephalosporins | ELI LILLY AND COMPANY (US) | 1980-06-17 | — | — | US | disclosed |
| US-4064343-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-3962227-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | PTGS1 2544/4885PDE4A 508/4885LMNA 2878/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | PTGS1 692/4885PDE4A 61/4885LMNA 3267/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | PTGS1 2544/4885PDE4A 508/4885LMNA 2878/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | PTGS1 2544/4885PDE4A 508/4885LMNA 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.